Global Transdermal Drug Delivery Partnering 2010 - 2015

Table of Content

Executive Summary

Chapter 1 – Introduction

Chapter 2 – Trends in transdermal drug delivery dealmaking

2.1. Introduction
2.2. Transdermal drug delivery partnering over the years
2.3. Big pharma transdermal drug delivery dealmaking activity
2.4. Transdermal drug delivery partnering by industry type
2.5. Transdermal drug delivery partnering by deal type
2.6. Transdermal drug delivery partnering by disease type
 
Chapter 3 –Average financial deal terms for transdermal drug delivery partnering

3.1 Transdermal drug delivery deals by headline values
3.2 Transdermal drug delivery upfront payments
3.3 Transdermal drug delivery milestone payments
3.4 Transdermal drug delivery royalty rates
 
Chapter 4 – Leading transdermal drug delivery deals

4.1. Introduction
4.2. Most active in transdermal drug delivery partnering
4.3. Top transdermal drug delivery deals by value
 
Chapter 5 – Transdermal drug delivery partnering dealmaking directory

5.1. Introduction
5.2. Company A-Z
5.3. By deal type
5.4. By stage of development
5.5. By industry sector
5.6. By therapy area

List of Table

NA

List of Chart

Figure 1: Transdermal drug delivery partnering since 2010
Figure 2: Big pharma – top 50 – Transdermal drug delivery deals 2010 to 2015
Figure 3: Big pharma transdermal drug delivery deal frequency – 2010 to 2015
Figure 4: Transdermal drug delivery partnering by industry sector since 2010
Figure 5: Transdermal drug delivery partnering by deal type since 2010
Figure 6: Transdermal drug delivery partnering by disease type since 2010
Figure 7: Transdermal drug delivery deals with a headline value
Figure 8: Transdermal drug delivery deals with an upfront value
Figure 9: Transdermal drug delivery deals with a milestone value
Figure 10: Transdermal drug delivery deals with a royalty rate value
Figure 11: Active transdermal drug delivery dealmaking activity– 2010 to 2015
Figure 12: Top transdermal drug delivery deals by value since 2010